For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

由此可见，mRNA-4157（V940）联合帕博利珠单抗在黑色素瘤患者中耐受性良好。 而mRNA-4157（V940）预计最早在2025年上市，这将会是全球首款mRNA肿瘤疫苗。

默沙东正与辉瑞和安斯泰来合作，针对这一组合进行评估，将其作为尿路上皮癌多阶段广泛临床开发计划的一部分，其中包括两项针对肌层浸润性膀胱癌的3期临床试验正在进行中，即KEYNOTE-B15和KEYNOTE-905试验。

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...

周一，Summit Therapeutics (SMMT.US)股价一路暴涨。截至发稿，该股涨幅达55.99%，报19.14美元。这是自2017年9月11日收于16.00美元以来的首次创纪录收盘新高，而且，今年迄今为止增长了632.38％。

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...

Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...

Patients with early-stage triple-negative breast cancer tended to have improved survival with neoadjuvant pembrolizumab plus ...

Discover the results from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, presented at ESMO 2024, Barcelona, Spain ...

在初步分析中，与单一疗法pembrolizumab相比，ivonescimab单药治疗在试验的主要终点无进展生存期方面表现出统计学上显着改善，从而成为在 NSCLC 随机后期临床试验中第一个比pembrolizumab获得临床意义益处的药物。

Longer follow-up from the phase 3 AMBASSADOR trial showed adjuvant pembrolizumab to demonstrate a statistically significant ...